- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02247986
Investigating the Impact of Methylphenidate on Neural Response in Disruptive Behavioral Disorder
Background:
- Disruptive behavior is a common problem for children and adolescents. It can be treated with some success with stimulant medicine. Researchers want to learn more about how this works.
Objective:
- To learn how the brain changes when taking the medicine methylphenidate for behavior problems.
Eligibility:
- Children ages 10 17 with conduct disorder and/or attention deficit disorder.
- Healthy volunteers the same age.
Design:
- Participants will be screened under a separate protocol.
- Participants will have two 3-hour sessions at the clinic. Girls who are menstruating will have a pregnancy test before their scans.
- Visit 1: All participants will:
- Perform simple tests on a computer.
- Fill out a questionnaire along with their parent or guardian.
- Have an MRI scan. A magnetic field and radio waves take pictures of the brain. Participants will lie on a table that slides into a metal cylinder. A coil will be placed over their head. They will be in the scanner for 60 minutes, lying still or performing a simple task. They will practice the task before the scan. A computer screen will show them task information during the scan. The scanner makes loud knocking sounds. Participants will get earplugs. Their parent or guardian can stay with them during the scan.
- Only participants with behavior disorders will:
- Take a pill of the study medicine or placebo.
- Be monitored for any side effects.
- Visit 2 is a repeat of Visit 1, except participants who got a pill in Visit 1 will get the other pill in Visit 2. For healthy volunteers, the 2 visits are exactly the same.
Study Overview
Status
Intervention / Treatment
Detailed Description
OBJECTIVE:
To determine the impact, as indexed by BOLD response, of the administration of dopaminergic agonist (methylphenidate) on the pathophysiology of CD/ODD.
STUDY POPULATION:
Youth with CD/ODD and typically developing (TD) youth.
DESIGN:
The study will involve a 2 session design (methylphenidate [MPH] vs. placebo). Patients with CD/ODD will participate in both sessions. TD youth will be tested for 2 sessions (no medication) to provide an index of typical task response. Activity within regions of interest identified from the TD youth will be used to determine whether MPH reduces differences in BOLD response in CD/ODD relative to TD youth. ICU scores and current ADHD symptomatology will be used as covariates to determine whether these variables moderate the putative increase in BOLD response in target regions in the patients with CD.
OUTCOME MEASURES:
Principle dependent measures will be BOLD responses as measured through core tasks.
Study Type
Phase
- Phase 2
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
- INCLUSION CRITERIA
Youth with CD
- 10-17 years of age.
A current diagnosis of CD as determined by the Kiddie-SADS, lifetime version.
- Youth in the CD+comorbid ADHD group will also meet diagnostic criteria for ADHD.
- Youth in the CD without comorbid ADHD group will specifically not meet diagnostic criteria for ADHD.
- Youth with CD shouldmust be na(SqrRoot) ve to psychoactive medication (such as: methylphenidate and amphetamine).
TD youth
- 10-17 years of age.
- No current psychiatric diagnosis, as determined by the Kiddie-SADS, lifetime version.
EXCLUSION CRITERIA
Exclusion criteria for youth with CD (with or without ADHD)
- Comorbid psychotic, major mood, tic, pervasive developmental, and substance abuse disorders.
- Presence of comorbid ADHD is exclusory for the group of patients with CD without ADHD
- History of known structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems
- Current weight less than 25kg or over 90kg
Exclusion criteria for all participants (CD with ADHD, CD without ADHD and TD)
- History of serious CNS disease disorder (examples aresuch as: history of seizure, epilepsy, brain tumor, brain hemorrhage, and major CNS infection such as meningitis or encephalitis)
- Previous history of known structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems
- Current use of any psychiatric medications and centrally acting medications (such as stimulants, non-stimulant ADHD medications, antidepressants, anxiolytics, antipsychotics and anti-epilepsy medications), and past history of use of psychoactive medication (such as methylphenidate and amphetamine)
- A positive urine pregnancy test
- A Positive urine toxicology, History/current diagnosis of substance abuse/dependence
- Suicidal or homicidal ideation within the past 6 months.
- Wechsler Abbreviated Scale of Intelligence (WASI) (D. Wechsler, 1999) scores <70
- Metal in body (i.e., hearing aid, cardiac pacemaker, bone plates, etc), claustrophobia, or any other condition that would preclude fMRI scanning.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Patients with CD will show an increase in the amygdala response to fearful expressions such that the difference between BOLD response in patients and TDs is reduced on MPH relative to placebo. ICU score will be a significant covariate of the inc...
Time Frame: 2 years from the initiation of the protocol
|
2 years from the initiation of the protocol
|
Patients with CD will show an increase in reward prediction errors and reward expected value signaling within striatum and ventromedial frontal cortex (vmPFC) such that the difference between BOLD response in patients and TDs is reduced on MPH r...
Time Frame: 2 years from the initiation of the protocol
|
2 years from the initiation of the protocol
|
Patients with CD will show an increase in conflict related signaling within dorsomedial, lateral and parietal cortices such that the difference between BOLD response in patients and TDs is reduced on MPH relative to placebo. Current ADHD sympto...
Time Frame: 2 years from the initiation of the protocol
|
2 years from the initiation of the protocol
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Symptom profiles measured by the clinical scales listed in the protocol (CBCL, the ICU, Connor s parent report on ADHD symptom) will be significantly related to the BOLD signal changes after methylphenidate administration.
Time Frame: 2 years from the initiation of the protocol
|
2 years from the initiation of the protocol
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Waschbusch DA, Carrey NJ, Willoughby MT, King S, Andrade BF. Effects of methylphenidate and behavior modification on the social and academic behavior of children with disruptive behavior disorders: the moderating role of callous/unemotional traits. J Clin Child Adolesc Psychol. 2007 Oct-Dec;36(4):629-44. doi: 10.1080/15374410701662766.
- Blair RJ. Neurocognitive models of aggression, the antisocial personality disorders, and psychopathy. J Neurol Neurosurg Psychiatry. 2001 Dec;71(6):727-31. doi: 10.1136/jnnp.71.6.727.
- White SF, Pope K, Sinclair S, Fowler KA, Brislin SJ, Williams WC, Pine DS, Blair RJ. Disrupted expected value and prediction error signaling in youths with disruptive behavior disorders during a passive avoidance task. Am J Psychiatry. 2013 Mar;170(3):315-23. doi: 10.1176/appi.ajp.2012.12060840.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Pathologic Processes
- Neurodevelopmental Disorders
- Disease
- Conduct Disorder
- Attention Deficit and Disruptive Behavior Disorders
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Dopamine Agents
- Dopamine Uptake Inhibitors
- Central Nervous System Stimulants
- Methylphenidate
Other Study ID Numbers
- 140193
- 14-M-0193
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Conduct Disorder
-
Istanbul Bilgi UniversityCenter for Regulation Focused PsychotherapyRecruitingChildhood Externalizing Disorder | Childhood Oppositional Defiant Disorder | Childhood Conduct DisorderTurkey
-
Virginia Commonwealth UniversityNational Institute of Mental Health (NIMH)RecruitingConduct Disorder | Conduct Disorders in Adolescence | Conduct Disorders in Children | Callous-Unemotional TraitsUnited States
-
Finnish Institute for Health and WelfareUniversity of HelsinkiCompletedConduct Disorders in Children
-
National Taiwan University HospitalCompletedAttention Deficit Disorder With Hyperactivity | Conduct Disorders in Adolescence | Autistic Spectrum DisorderTaiwan
-
Oregon Research Behavioral Intervention Strategies...RecruitingConduct Disorder | Oppositional Defiant DisorderUnited States
-
Region SkaneRecruitingGambling Disorder | Gaming DisorderSweden
-
Indonesia UniversityRadboud University Medical CenterNot yet recruiting
-
Karolinska InstitutetDeakin UniversityRecruiting
-
Taipei City HospitalRecruiting
-
University Hospital, LilleMinistry of Health, FranceNot yet recruiting
Clinical Trials on Methylphenidate Hydrochloride
-
Massachusetts General HospitalMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.Completed
-
Massachusetts General HospitalMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.Completed
-
Massachusetts General HospitalMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.CompletedAttention Deficit Hyperactivity DisorderUnited States
-
Massachusetts General HospitalMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.Completed
-
Purdue Pharma LPTerminatedAttention-Deficit/Hyperactivity DisorderUnited States
-
Novartis PharmaceuticalsCompletedAttention Deficit/Hyperactivity DisorderGermany, United States, Belgium, Colombia, Denmark, Sweden
-
Monash Medical CentreMonash UniversityRecruiting
-
Ironshore Pharmaceuticals and Development, IncCompletedAttention Deficit Hyperactivity DisorderUnited States
-
Ironshore Pharmaceuticals and Development, IncCompletedAttention Deficit Hyperactivity DisorderUnited States
-
Eli Lilly and CompanyCompletedAttention Deficit Hyperactivity DisorderChina, Mexico, Korea, Republic of